HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Saposins

A group of four homologous sphingolipid activator proteins that are formed from proteolytic cleavage of a common protein precursor molecule referred to as prosaposin.
Also Known As:
Co-beta-Glucosidase; Coglucosidase; Gaucher Activator Protein; Glucosylceramidase Activator; SAP-1 Sphingolipid Activator; SAP-A Protein; SAP-C Protein; SAP-D Protein; Saposin A; Saposin B; Saposin C; Saposin D; Sphingolipid Activator Protein 1; Sphingolipid Activator Protein 2; Sphingolipid Activator Protein-1; Testibumin; beta-Glucosidase Activator Protein; beta-Glucosidase Stimulating Protein; Co beta Glucosidase; SAP 1 Sphingolipid Activator; SAP A Protein; SAP C Protein; SAP D Protein; Sphingolipid Activator, SAP-1; beta Glucosidase Activator Protein; beta Glucosidase Stimulating Protein
Networked: 103 relevant articles (2 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Qi, Xiaoyang: 10 articles (06/2015 - 09/2009)
2. Chu, Zhengtao: 8 articles (06/2015 - 09/2009)
3. Matsuda, Junko: 7 articles (11/2015 - 09/2003)
4. Grabowski, Gregory A: 7 articles (02/2015 - 10/2005)
5. Sun, Ying: 7 articles (02/2015 - 10/2005)
6. Sandhoff, Konrad: 6 articles (12/2013 - 06/2005)
7. Witte, David P: 6 articles (03/2010 - 10/2005)
8. Ran, Huimin: 5 articles (01/2011 - 04/2007)
9. Suzuki, Kunihiko: 5 articles (08/2010 - 09/2003)
10. Motta, Marialetizia: 4 articles (11/2014 - 08/2010)

Related Diseases

1. Gaucher Disease (Gaucher's Disease)
2. Metachromatic Leukodystrophy (Sulfatide Lipidosis)
3. Ischemia
11/01/2001 - "To investigate the effects of an 18-mer peptide comprising the hydrophilic sequence of the rat saposin C domain (18MP) on this sustained neuronal degeneration, an intracerebroventricular 18MP infusion was initiated 3 days after ischemia. "
03/01/1999 - "Furthermore, a saposin C fragment comprising the 18-mer peptide bound to synaptosomal fractions of the cerebral cortex, and this binding decreased at the 1st day after MCA occlusion and recovered to the preischemic level at the 7th day after ischemia. "
01/01/2000 - "Prosaposin is a 517 amino acid membrane component and secreted protein(5,7,9) that is proteolytically cleaved to generate the four small glycoproteins; saposins A, B, C and D.(9,13,19) Prosaposin's ability to promote neurite outgrowth(31) and to protect neurons from programmed cell death(28) in vitro, as well as to rescue neurons from ischemia and other damage in vivo(11,12,15,25) implied that prosaposin was neurotrophic/neuroprotectant.(1,7,24,31) The neurotrophic sequence of prosaposin was isolated to smaller peptide fragments termed prosaptides(15,31) within the amino terminal portion of saposin C.(1,6,8,10,17,20,21,28) The proposed use of synthetic prosaptides as peripherally administered neuroprotective and/or neurotrophic therapeutic agents has stemmed from their ability to cross the blood-brain barrier,(27) as well as their reported neurotrophic activity in vitro.(15,23,31) Few studies, however, have attempted to characterize these peptides, presumably due to their reported instability following peripheral administration.(27) With the recent design of a stable 11-mer retro-inverso prosaptide,(15,31) it has become feasible to investigate the pharmacological effects of a stable version of these peptides in the validated rabbit spinal cord ischemia model that has been used extensively in the development of therapeutics to treat ischemic stroke.(4,14,16,18) Our results show not only that prosaptide was not neurotrophic/neuroprotectant in vivo, but rather it worsened ischemia-induced behavioral deficits."
4. Spinal Cord Ischemia
01/01/2000 - "Prosaposin is a 517 amino acid membrane component and secreted protein(5,7,9) that is proteolytically cleaved to generate the four small glycoproteins; saposins A, B, C and D.(9,13,19) Prosaposin's ability to promote neurite outgrowth(31) and to protect neurons from programmed cell death(28) in vitro, as well as to rescue neurons from ischemia and other damage in vivo(11,12,15,25) implied that prosaposin was neurotrophic/neuroprotectant.(1,7,24,31) The neurotrophic sequence of prosaposin was isolated to smaller peptide fragments termed prosaptides(15,31) within the amino terminal portion of saposin C.(1,6,8,10,17,20,21,28) The proposed use of synthetic prosaptides as peripherally administered neuroprotective and/or neurotrophic therapeutic agents has stemmed from their ability to cross the blood-brain barrier,(27) as well as their reported neurotrophic activity in vitro.(15,23,31) Few studies, however, have attempted to characterize these peptides, presumably due to their reported instability following peripheral administration.(27) With the recent design of a stable 11-mer retro-inverso prosaptide,(15,31) it has become feasible to investigate the pharmacological effects of a stable version of these peptides in the validated rabbit spinal cord ischemia model that has been used extensively in the development of therapeutics to treat ischemic stroke.(4,14,16,18) Our results show not only that prosaptide was not neurotrophic/neuroprotectant in vivo, but rather it worsened ischemia-induced behavioral deficits."
5. Stroke (Strokes)
01/01/2000 - "Prosaposin is a 517 amino acid membrane component and secreted protein(5,7,9) that is proteolytically cleaved to generate the four small glycoproteins; saposins A, B, C and D.(9,13,19) Prosaposin's ability to promote neurite outgrowth(31) and to protect neurons from programmed cell death(28) in vitro, as well as to rescue neurons from ischemia and other damage in vivo(11,12,15,25) implied that prosaposin was neurotrophic/neuroprotectant.(1,7,24,31) The neurotrophic sequence of prosaposin was isolated to smaller peptide fragments termed prosaptides(15,31) within the amino terminal portion of saposin C.(1,6,8,10,17,20,21,28) The proposed use of synthetic prosaptides as peripherally administered neuroprotective and/or neurotrophic therapeutic agents has stemmed from their ability to cross the blood-brain barrier,(27) as well as their reported neurotrophic activity in vitro.(15,23,31) Few studies, however, have attempted to characterize these peptides, presumably due to their reported instability following peripheral administration.(27) With the recent design of a stable 11-mer retro-inverso prosaptide,(15,31) it has become feasible to investigate the pharmacological effects of a stable version of these peptides in the validated rabbit spinal cord ischemia model that has been used extensively in the development of therapeutics to treat ischemic stroke.(4,14,16,18) Our results show not only that prosaptide was not neurotrophic/neuroprotectant in vivo, but rather it worsened ischemia-induced behavioral deficits."

Related Drugs and Biologics

1. Saposins
2. Glycoproteins (Glycoprotein)
3. prosaptide
4. Peptides
5. Peptide Fragments
6. Glucosylceramidase (Glucocerebrosidase)
7. Cerebroside-Sulfatase (Arylsulfatase A)
8. Glycosphingolipids
9. Sphingolipid Activator Proteins
10. Enzymes

Related Therapies and Procedures

1. Therapeutics
2. Bone Marrow Transplantation (Transplantation, Bone Marrow)
3. Heterologous Transplantation (Xenotransplantation)